Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder
Institutions: Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, Duke University, Duke Cancer Institute, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Harvard University, Massachusetts General Hospital, University of California, San Francisco, Center for Clinical and Cosmetic Research, Kaiser Permanente, The University of Texas MD Anderson Cancer Center, The Ohio State University Wexner Medical Center, The Ohio State University, Stanford University, Saint Luke's Hospital, Rush University Medical Center, Partnership for Health Analytic Research
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4298147561